Safety Comparison of Four Types of Rabies Vaccines in Patients with WHO Category II Animal Exposure: An Observation Based on Different Age Groups

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Nov 29

PMID 27893654

Citations 8

Authors

Jun Peng

Sha Lu

Zhenggang Zhu

Man Zhang

Quan Hu

Yuan Fang

Affiliations

Soon will be listed here.

Abstract

To evaluate the safeties of 4 types of rabies vaccines for patients with WHO category II animal exposure, especially in different age groups.A total of 4000 patients with WHO category II animal exposure were randomly divided into 4 vaccine groups, and were respectively given with Vaccines A, B, C, and D. And subjects in each vaccine group were divided into 4 age groups (≤5, 5-18, 19-60, and ≥60-year-old groups). Then adverse events (including local and systemic ones) were recorded and compared. Consequently, except for Vaccine B, patients under the age of 5 in Groups A, C, and D suffered from more adverse reactions than those in other age groups. Furthermore, for the children aged less than 5 years, incidence of adverse events following administration of Vaccine B, with the dose of 0.5 mL and production of bioreactor systems, was significantly lower than Vaccines A and D.Our data showed that rabies vaccines with smaller doses and more advanced processing techniques are of relatively high safety for the patients, especially for the young children.

Citing Articles

A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens.

Lv H, Chen X, Xing B, Hu X, Zhang X, Shen Y Sci Rep. 2025; 15(1):7079.

PMID: 40016280 PMC: 11868620. DOI: 10.1038/s41598-025-88361-1.

Evaluating adherence to government recommendations for post-exposure rabies vaccine among animal-bite victims: A hospital-based study in Bangladesh.

Tamanna S, Yasmin D, Ghosh S, Rahaman M, Dey A, Das T PLOS Glob Public Health. 2023; 3(11):e0002506.

PMID: 37963109 PMC: 10645289. DOI: 10.1371/journal.pgph.0002506.

Post-Exposure Prophylactic Vaccination against Rabies: A Systematic Review.

Ahmad N, Mohammed Nawi A, Jamhari M, Nurumal S, Mansor J, Zamzuri M Iran J Public Health. 2022; 51(5):967-977.

PMID: 36407746 PMC: 9643235. DOI: 10.18502/ijph.v51i5.9412.

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.

Wang S, Sun J, Liu P, Luo L, Li J, Zhu F Hum Vaccin Immunother. 2022; 18(1):2027714.

PMID: 35192787 PMC: 8993064. DOI: 10.1080/21645515.2022.2027714.

Response to letter to the editor on analysis.

Huang S, Zhu Z, Hu Q Hum Vaccin Immunother. 2019; 15(9):2127-2128.

PMID: 30932728 PMC: 6773394. DOI: 10.1080/21645515.2019.1596714.

References

Warrell M . Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis. 2012; 10(1):1-15. DOI: 10.1016/j.tmaid.2011.12.005. View

Kallel H, Rourou S, Majoul S, Loukil H . A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor. Appl Microbiol Biotechnol. 2003; 61(5-6):441-6. DOI: 10.1007/s00253-003-1245-3. View

Fang Y, Chen L, Liu M, Zhu Z, Zhu Z, Hu Q . Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: a study based on different age groups. PLoS Negl Trop Dis. 2014; 8(12):e3412. PMC: 4270726. DOI: 10.1371/journal.pntd.0003412. View

Gallegos Gallegos R, Espinosa Larios E, Ramos Ramirez L, Kretschmer Schmid R, Setien A . Rabies veterinary virus vaccine produced in BHK-21 cells grown on microcarriers in a bioreactor. Arch Med Res. 1995; 26(1):59-63. View

Hu Q, Liu M, Zhu Z, Zhu Z, Lu S . Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China. Hum Vaccin Immunother. 2014; 10(6):1645-9. PMC: 5396232. DOI: 10.4161/hv.28420. View

Permpalung N, Wongrakpanich S, Korpaisarn S, Tanratana P, Angsanakul J . Trend of human rabies prophylaxis in developing countries: toward optimal rabies immunization. Vaccine. 2013; 31(38):4079-83. DOI: 10.1016/j.vaccine.2013.06.083. View

Shanbag P, Shah N, Kulkarni M, Juvekar M, Madhusudana S, Vakil H . Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). Hum Vaccin. 2008; 4(5):365-9. DOI: 10.4161/hv.4.5.5987. View

Mendonca R, Ioshimoto L, Mendonca R, Valentini E, Becak W, Raw I . Preparation of human rabies vaccine in VERO cell culture using a microcarrier system. Braz J Med Biol Res. 1993; 26(12):1305-17. View

Chakradhar S . Biting back: vaccine efforts redoubled as rabies deadline looms. Nat Med. 2015; 21(1):8-10. DOI: 10.1038/nm0115-8. View

10.

Rajendran R, Lingala R, Vuppu S, Bandi B, Manickam E, Macherla S . Assessment of packed bed bioreactor systems in the production of viral vaccines. AMB Express. 2014; 4:25. PMC: 4052670. DOI: 10.1186/s13568-014-0025-z. View

11.

Ashwathnarayana D, Madhusudana S, Sampath G, Sathpathy D, Mankeshwar R, Ravish H . A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab). Vaccine. 2009; 28(1):148-51. DOI: 10.1016/j.vaccine.2009.09.090. View

12.

. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser. 2013; (982):1-139, back cover. View

13.

. Rabies vaccines: WHO position paper--recommendations. Vaccine. 2010; 28(44):7140-2. DOI: 10.1016/j.vaccine.2010.08.082. View

14.

WIKTOR T, Fernandes M, KOPROWSKI H . CULTIVATION OF RABIES VIRUS IN HUMAN DIPLOID CELL STRAIN WI-38. J Immunol. 1964; 93:353-66. View